Evidence map›Paper›PMID 42421040›Full record

ArticleHarm reduction journal2026

Integrating harm reduction interventions for older adults in opioid treatment programs: a qualitative study of patient and provider perspectives.

Wayne Kepner, Benjamin H Han, Annie L Nguyen, Raúl Bejarano-Romero, Nora Satybaldiyeva, Alison A Moore, Angela R Bazzi

Abstract read
In one paragraph

Article in Harm reduction journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wayne KepnerDepartment of Medicine, School of Medicine, University of California San Diego, 9500 Gilman Drive, San Diego, CA, 92093, USA.
Benjamin H HanDepartment of Medicine, School of Medicine, University of California San Diego, 9500 Gilman Drive, San Diego, CA, 92093, USA.
Annie L NguyenHerbert Wertheim School of Public Health, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.
Raúl Bejarano-RomeroDepartment of Medicine, School of Medicine, University of California San Diego, 9500 Gilman Drive, San Diego, CA, 92093, USA.
Nora SatybaldiyevaDepartment of Medicine, School of Medicine, University of California San Diego, 9500 Gilman Drive, San Diego, CA, 92093, USA.
Alison A MooreDepartment of Medicine, School of Medicine, University of California San Diego, 9500 Gilman Drive, San Diego, CA, 92093, USA.
Angela R BazziHerbert Wertheim School of Public Health, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA. abazzi@health.ucsd.edu.ORCID https://orcid.org/0000-0001-6828-1919

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
Cardiovascular and Chronic Disease Prevention Training ProgramT32HL161270 · NHLBI · STANFORD UNIVERSITY · PI CHRISTOPHER D GARDNER · 2022 to 2026
$2.6M
National Institute of Allergy and Infectious Diseases P30AI036214NHLBI NIH HHS T32 HL161270NHLBI NIH HHS T32HL161270NIAID NIH HHS P30 AI036214
6 · The paper itself

Abstract

backgroundThe prevalence of opioid use disorder (OUD) among older adults has increased rapidly, yet this population faces unique challenges in accessing harm reduction services within opioid treatment programs (OTPs). The objective of this study was to explore patient and provider perspectives on the acceptability and feasibility of delivering harm reduction interventions to older adults within OTPs.

methodsFrom June 2023 to February 2024, we conducted a qualitative study with two OTPs in San Diego County, California. Participants included 25 patients aged 55 and older receiving medications for OUD, and 15 OTP providers. Semi-structured interviews and thematic analysis focused exploring participants' beliefs, attitudes, and experiences with harm reduction interventions.

resultsBoth patients and providers expressed broad acceptability and perceived need for harm reduction services within OTPs. Key barriers identified included intersectional stigma related to age and substance use, lack of age-appropriate interventions, transportation challenges, and technological barriers. Strong patient-provider relationships were viewed as critical for successful implementation; patients emphasized the value of providers with lived experience. Providers highlighted implementation challenges, including resource constraints, sustainability concerns, and the need for integrated care models addressing complex medical and social needs. While providers viewed the frequent contact inherent in OTP settings as an opportunity for relationship building and service delivery, cognitive changes among some patients and multiple chronic conditions could complicate care provision.

conclusionPatients and providers report high acceptability for integrating harm reduction services within OTPs tailored to older adults, but significant barriers exist. Addressing these barriers through tailored interventions, improved accessibility, and efforts to reduce stigma may improve care for this vulnerable population. Implementation strategies should focus on establishing sustainable funding mechanisms, strong community partnerships, and ongoing provider training. Finally, harm reduction services may require regular review to ensure they accommodate the unique needs of older adults with OUD.

Indexed as

Harm ReductionOpiate Substitution TreatmentOpioid-Related DisordersAgedAttitude of Health PersonnelCaliforniaFemaleHumansMaleMiddle AgedPatient Acceptance of Health CareQualitative ResearchAagingHarm reductionImplementationMmethadoneOopioid use disorder

Identifiers

PMID42421040
PMCPMC13632238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.